Yusuke Miyazato

Yusuke Miyazato

Auto-generated profile, based on publicly available information

Yusuke Miyazato

Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 May 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YMYusuke Miyazato
Yusuke Miyazato
STShinya Tsuzuki
Shinya Tsuzuki
SMShinichiro Morioka
Shinichiro Morioka
MTMari Terada
Mari Terada
SKSatoshi Kutsuna
Satoshi Kutsuna
NONorio Ohmagari
Norio Ohmagari

28 May 2022 in Journal of Travel Medicine
Verified
Journal Article
Open access
PDF file
YMYusuke Miyazato
Yusuke Miyazato
MTMari Terada
Mari Terada
MUMugen Ujiie
Mugen Ujiie
SSSho Saito
Sho Saito
AMAkinari Moriya
Akinari Moriya
NONorio Ohmagari
Norio Ohmagari
On 24 July 2017, Sanofi Pasteur, yellow fever vaccine (YF-VAX) manufacturer, announced a vaccine shortage caused by manufacturing delays. 1 Consequently, some countries were forced to take compensatory measures. In the USA, expanded access was given to 17D-204 YF-VAX (Stamaril, Sanofi Pasteur SA, Lyon, France), under an investigational new drug protocol. 2 Canada adopted fractional dosing of YF-VAX, administering 1/5th of the normal dose. 3 In Japan, there is no regulatory system allowing emergency use of unlicensed medicines; 17D-204 YF-VAX was used as an alternative vaccine through an investigator-initiated clinical trial. 4 As a clinical trial, the study objective was set upon trial initiation to collect safety information related to the 17D-204 YF-VAX injection.

23 September 2021 in medRxiv
Verified
Preprint
Open access
PDF file
YMYusuke Miyazato
Yusuke Miyazato
STShinya Tsuzuki
Shinya Tsuzuki
SMShinichiro Morioka
Shinichiro Morioka
MTMari Terda
Mari Terda
SKSatoshi Kutsuna
Satoshi Kutsuna
NONorio Ohmagari
Norio Ohmagari
Background Long COVID has been a social concern. Though patient characteristics associated with developing long COVID are partially known, those associated with persisting it have not been identified. Methods We conducted a cross-sectional questionnaire survey of patients after COVID-19 recovery who visited the National Center for Global Health and Medicine between February 2020 and March 2021. Demographic and clinical data, and the presence and duration of long COVID were obtained. We identified factors associated with development and persistence of long COVID using multivariate logistic and linear regression analysis, respectively. Results We analyzed 457 of 526 responses (response rate, 86.9%). The median age was 47 years, and 378 patients (84.4%) had mild disease in acute phase. The number of patients with any symptoms after 6 and 12 months after onset or diagnosis were 120 (26.3%) and 40 (8.8%), respectively. Women were at risk for development of fatigue (OR 2.03, 95% CI 1.31-3.14), dysosmia (OR 1.91, 95% CI 1.24-2.93), dysgeusia (OR 1.56, 95% CI 1.02-2.39), and hair loss (OR 3.00, 95% CI 1.77-5.09), and were at risk for persistence of any symptoms (coefficient 38.0, 95% CI 13.3-62.8). Younger age and low body mass index were risk factors for developing dysosmia (OR 0.96, 95% CI 0.94-0.98, and OR 0.94, 95% CI 0.89-0.99, respectively) and dysgeusia (OR 0.98, 95% CI 0.96-1.00, and OR 0.93, 95% CI 0.88-0.98, respectively). Conclusion We identified risk factors for the persistence as well as development of long COVID. Many patients suffer from long-term residual symptoms, even in mild cases. Summary Our cross-sectional questionnaire survey of patients recovering from COVID-19 revealed that women, young age, and low body mass index were risk factors for the development of multiple symptoms, and that even mild cases of COVID-19 suffered from long-term residual symptoms.

17 November 2021 in IDCases
Verified
Journal Article
Open access
SISatoshi Ide
Satoshi Ide
SSSho Saito
Sho Saito
TATsubasa Akazawa
Tsubasa Akazawa
TFTakahito Furuya
Takahito Furuya
JMJunichi Masuda
Junichi Masuda
NONorio Ohmagari
Norio Ohmagari
Remdesivir is an antiviral drug that results in clinical improvement after five days of treatment and accelerates recovery by 31%. No studies have discussed the pharmacokinetic analysis of remdesivir in patients with severe COVID-19 requiring extracorporeal membrane oxygenation (ECMO). A 63-year-old American man who underwent mechanical ventilation and ECMO for severe COVID-19 was administered remdesivir for ten days. The loading dosage was 200 mg at 7 PM on day 12 and 100 mg daily at 0:00 PM from day 13–21, administered within 1 h. The pharmacokinetic analysis was performed. The serum creatinine concentration was within the normal range of 0.5–0.7 mg/dL during treatment. According to the pharmacokinetic analysis, the plasma concentrations of remdesivir and GS-441524 4 h after administration (C4) were 662 ng/mL and 58 ng/mL, respectively, and the concentrations 18 h after administration (C18) were 32 ng/mL and 44 ng/mL, respectively. Therefore, the half-life of remdesivir and GS-441524 was 3.2 and 35.1 h, respectively. Monitoring the plasma concentrations of remdesivir and GS-441524 in patients undergoing ECMO may be necessary.

20 October 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
TSTetsuya Suzuki
Tetsuya Suzuki
YAYusuke Asai
Yusuke Asai
SISatoshi Ide
Satoshi Ide
SFSaori Fukuda
Saori Fukuda
ATAkihito Tanaka
Akihito Tanaka
NONorio Ohmagari
Norio Ohmagari

30 September 2022 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
YMYusuke Miyazato
Yusuke Miyazato
NKNoriko Kinoshita
Noriko Kinoshita
MUMasaru Usui
Masaru Usui
TSToyotaka Sato
Toyotaka Sato
TMTohru Miyoshi-Akiyama
Tohru Miyoshi-Akiyama
NONorio Ohmagari
Norio Ohmagari
Background: Polymyxin E (colistin) is a last-resort antibiotic to treat infections caused by carbapenemase-producing Enterobacteriaceae (CPE). However, reports of CPEs resistant to colistin have been increasing, and the mcr genes are emerging as resistance mechanisms. Among them, plasmid-mediate mcr-9 is known to be associated with colistin resistance, whereas reports on chromosomal mcr-9 and its association with colistin resistance in humans are few. Case presentation: We identified Enterobacter asburiae harboring mcr-9 and blaIMP-60 in the pleural fluid of a patient with empyema. The long-read sequencing technique revealed that these genes were located on its chromosome. Despite the lack of exposure to colistin, the organism showed microcolonies in the inhibition circle in the E-test and disk diffusion test. Antibiotic susceptibility testing by broth microdilution confirmed its resistance to colistin. Conclusion: Our case report showed that mcr-9 can be present not only on plasmids but also on the chromosome in E. asburiae, and that the presence of mcr-9 on its chromosome may influence its susceptibility to colistin.